Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 29.7% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 269,700 shares, a decrease of 29.7% from the December 15th total of 383,700 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 6.8% of the shares of the stock are sold short.

Allarity Therapeutics Trading Down 2.0 %

Shares of Allarity Therapeutics stock opened at $0.99 on Thursday. The firm’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $2.88. Allarity Therapeutics has a twelve month low of $0.90 and a twelve month high of $299.94.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.